Aclarion board unanimously rejects $4 per share unsolicited buyout offer

Aclarion (NASDAQ:ACON) announced that its Board of Directors has unanimously rejected an unsolicited, non-binding proposal from Echo Lake Capital to acquire the company at a price of $4 per share.

Following a comprehensive review conducted in consultation with its independent financial and legal advisors, the Board concluded that the proposal is not in the best interests of Aclarion and its shareholders.

In its public response, the Aclarion Board outlined several primary concerns regarding the structure and valuation of the offer.

Directors determined that the $4 per share price significantly undervalues the company’s intrinsic worth, particularly when accounting for its proprietary strategic assets and long-term growth trajectory in the medical technology sector.

Furthermore, the Board noted that the proposal relies on Aclarion's own existing cash reserves to finance the acquisition, a structure that the directors characterized as disproportionately beneficial to Echo Lake Capital rather than to Aclarion's broader shareholder base.

The company affirmed its commitment to maximizing shareholder value and stated that the Board remains open to evaluating future proposals that appropriately reflect the company’s true value and competitive positioning.